Hepatic Steatosis, Hepatic Fibrosis, and Metabolic Dysfunction–Associated Steatotic Liver Disease in Schizophrenia Patients

Key Points

• The study aims to investigate the prevalence of hepatic steatosis and fibrosis among schizophrenia patients on antipsychotic medication.
• Cross-sectional analysis of schizophrenia patients
• Assessment of hepatic steatosis and fibrosis
• Evaluation of metabolic dysfunction associated with liver disease
• Approximately one-third of patients exhibit hepatic steatosis and metabolic dysfunction-associated fatty liver disease (MAFLD)
• More than one-fourth of patients have hepatic fibrosis
• These findings highlight the importance of monitoring liver health in high-metabolic-risk antipsychotic users